Etripamil Nasal Spray: Therapeutic Potential for Treating Paroxysmal Supraventricular Tachycardia

Patients with arrythmias are at an increased risk of heart-related comorbidities and complications. Specifically, patients with paroxysmal supraventricular tachycardia (PSVT), a type of arrythmia, are at increased risk of lightheadedness or shortness of breath, due to the increased rate of the heart...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of cardiovascular drugs : drugs, devices, and other interventions Vol. 23; no. 5; pp. 471 - 475
Main Authors Huston, Jessica, Genovese, Ariana, Ashchi, Andrea, DeLuca, Amanda, Wiener, Jordyn, Deeb, Elias, Deeb, Alexander, Goldfaden, Rebecca F.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.09.2023
Springer Nature B.V
Subjects
Cardiac arrhythmia
Cardiology
Cardioversion
Drug dosages
Heart
Leading Article
Medicine
Medicine & Public Health
Oral administration
Pharmacology/Toxicology
Pharmacotherapy
Online AccessGet full text

Cover

More Information
Summary:Patients with arrythmias are at an increased risk of heart-related comorbidities and complications. Specifically, patients with paroxysmal supraventricular tachycardia (PSVT), a type of arrythmia, are at increased risk of lightheadedness or shortness of breath, due to the increased rate of the heartbeat. Most patients are prescribed oral medications to control their heart rates and maintain a normal heart rhythm. Researchers have been tasked with discovering alternative treatment options with new delivery methods to treat arrythmias such as PSVT. A nasal spray was subsequently designed and is currently undergoing clinical studies. This review aims to present and discuss the current clinical and scientific evidence pertaining to etripamil.
ISSN:1175-3277
1179-187X
DOI:10.1007/s40256-023-00589-2